Ono Pharmaceutical Co., Ltd. (TYO:4528)
Japan flag Japan · Delayed Price · Currency is JPY
1,737.00
+10.00 (0.58%)
Sep 16, 2025, 10:45 AM JST

Ono Pharmaceutical Company Description

Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide.

It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia.

The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis.

In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis.

The company has collaborations with Adimab LLC to discover novel antibody drugs; Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and Sibylla Biotech for central nervous system disorders.

Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.

Ono Pharmaceutical Co., Ltd.
CountryJapan
Founded1717
IndustryDrug Manufacturers - General
SectorHealthcare
Employees4,287
CEOGyo Sagara

Contact Details

Address:
8-2, Kyutaromachi 1-chome
Osaka, 541-8564
Japan
Phone81 6 6263 5670
Websiteono-pharma.com

Stock Details

Ticker Symbol4528
ExchangeTokyo Stock Exchange
Stock TypeCommon Stock
Fiscal YearApril - March
Reporting CurrencyJPY
ISIN NumberJP3197600004
SIC Code2834

Key Executives

NamePosition
Gyo SagaraChief Executive Officer
Masaki ItoChief Financial Officer
Toichi TakinoChief Operating Officer